1
|
Vidana Gamage HE, Albright ST, Smith AJ, Farmer R, Shahoei SH, Wang Y, Fink EC, Jacquin E, Weisser E, Bautista RO, Henn MA, Schane CP, Nelczyk AT, Ma L, Das Gupta A, Bendre SV, Nguyen T, Tiwari S, Krawczynska N, He S, Tjoanda E, Chen H, Sverdlov M, Gann PH, Boidot R, Vegran F, Fanning SW, Apetoh L, Hergenrother PJ, Nelson ER. Development of NR0B2 as a therapeutic target for the re-education of tumor associated myeloid cells. Cancer Lett 2024; 597:217086. [PMID: 38944231 DOI: 10.1016/j.canlet.2024.217086] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2024] [Revised: 06/20/2024] [Accepted: 06/25/2024] [Indexed: 07/01/2024]
Abstract
Immune checkpoint blockade (ICB) has had limited utility in several solid tumors such as breast cancer, a major cause of cancer-related mortality in women. Therefore, there is considerable interest in alternate strategies to promote an anti-cancer immune response. A paper co-published in this issue describes how NR0B2, a protein involved in cholesterol homeostasis, functions within myeloid immune cells to modulate the inflammasome and reduce the expansion of immune-suppressive regulatory T cells (Treg). Here, we develop NR0B2 as a potential therapeutic target. NR0B2 in tumors is associated with improved survival for several cancer types including breast. Importantly, NR0B2 expression is also prognostic of ICB success. Within breast tumors, NR0B2 expression is inversely associated with FOXP3, a marker of Tregs. While a described agonist (DSHN) had some efficacy, it required high doses and long treatment times. Therefore, we designed and screened several derivatives. A methyl ester derivative (DSHN-OMe) emerged as superior in terms of (1) cellular uptake, (2) ability to regulate expected expression of genes, (3) suppression of Treg expansion using in vitro co-culture systems, and (4) efficacy against the growth of primary and metastatic tumors. This work identifies NR0B2 as a target to re-educate myeloid immune cells and a novel ligand with significant anti-tumor efficacy in preclinical models.
Collapse
Affiliation(s)
- Hashni Epa Vidana Gamage
- Department of Molecular and Integrative Physiology, University of Illinois at Urbana-Champaign, Illinois, USA
| | - Samuel T Albright
- Department of Chemistry, University of Illinois at Urbana-Champaign, Illinois, USA
| | - Amanda J Smith
- Department of Chemistry, University of Illinois at Urbana-Champaign, Illinois, USA
| | - Rachel Farmer
- Department of Chemistry, University of Illinois at Urbana-Champaign, Illinois, USA
| | - Sayyed Hamed Shahoei
- Department of Molecular and Integrative Physiology, University of Illinois at Urbana-Champaign, Illinois, USA
| | - Yu Wang
- Department of Molecular and Integrative Physiology, University of Illinois at Urbana-Champaign, Illinois, USA
| | - Emma C Fink
- Department of Cancer Biology, Loyola University Chicago Health Sciences Campus, Illinois, USA
| | | | - Erin Weisser
- Department of Molecular and Integrative Physiology, University of Illinois at Urbana-Champaign, Illinois, USA
| | - Rafael O Bautista
- Department of Molecular and Integrative Physiology, University of Illinois at Urbana-Champaign, Illinois, USA
| | - Madeline A Henn
- Department of Molecular and Integrative Physiology, University of Illinois at Urbana-Champaign, Illinois, USA
| | - Claire P Schane
- Department of Molecular and Integrative Physiology, University of Illinois at Urbana-Champaign, Illinois, USA
| | - Adam T Nelczyk
- Department of Molecular and Integrative Physiology, University of Illinois at Urbana-Champaign, Illinois, USA
| | - Liqian Ma
- Department of Molecular and Integrative Physiology, University of Illinois at Urbana-Champaign, Illinois, USA
| | - Anasuya Das Gupta
- Department of Molecular and Integrative Physiology, University of Illinois at Urbana-Champaign, Illinois, USA
| | - Shruti V Bendre
- Department of Molecular and Integrative Physiology, University of Illinois at Urbana-Champaign, Illinois, USA
| | - Tiffany Nguyen
- Department of Molecular and Integrative Physiology, University of Illinois at Urbana-Champaign, Illinois, USA
| | - Srishti Tiwari
- Department of Molecular and Integrative Physiology, University of Illinois at Urbana-Champaign, Illinois, USA
| | - Natalia Krawczynska
- Department of Molecular and Integrative Physiology, University of Illinois at Urbana-Champaign, Illinois, USA; Beckman Institute for Advanced Science and Technology, University of Illinois at Urbana-Champaign, Illinois, USA
| | - Sisi He
- Department of Molecular and Integrative Physiology, University of Illinois at Urbana-Champaign, Illinois, USA
| | - Evelyn Tjoanda
- Department of Molecular and Integrative Physiology, University of Illinois at Urbana-Champaign, Illinois, USA
| | - Hong Chen
- Food Science & Human Nutrition, University of Illinois at Urbana-Champaign, Illinois, USA
| | - Maria Sverdlov
- Research Histology and Tissue Imaging Core, University of Illinois at Chicago, Illinois, USA
| | - Peter H Gann
- Research Histology and Tissue Imaging Core, University of Illinois at Chicago, Illinois, USA; Department of Pathology, University of Illinois at Chicago, Illinois, USA
| | - Romain Boidot
- Unit of Molecular Biology, Department of Biology and Pathology of Tumors, Georges-Francois Leclerc Cancer Center, Dijon, France; ICMUB UMR CNRS 6302, Dijon, France
| | | | - Sean W Fanning
- Department of Cancer Biology, Loyola University Chicago Health Sciences Campus, Illinois, USA
| | | | - Paul J Hergenrother
- Department of Chemistry, University of Illinois at Urbana-Champaign, Illinois, USA; Carl R. Woese Institute for Genomic Biology- Anticancer Discovery from Pets to People, University of Illinois at Urbana-Champaign, Illinois, USA; Cancer Center at Illinois, University of Illinois Urbana-Champaign, University of Illinois at Urbana-Champaign, Illinois, USA
| | - Erik R Nelson
- Department of Molecular and Integrative Physiology, University of Illinois at Urbana-Champaign, Illinois, USA; Beckman Institute for Advanced Science and Technology, University of Illinois at Urbana-Champaign, Illinois, USA; Carl R. Woese Institute for Genomic Biology- Anticancer Discovery from Pets to People, University of Illinois at Urbana-Champaign, Illinois, USA; Cancer Center at Illinois, University of Illinois Urbana-Champaign, University of Illinois at Urbana-Champaign, Illinois, USA; Division of Nutritional Sciences, University of Illinois Urbana-Champaign, University of Illinois at Urbana-Champaign, Illinois, USA.
| |
Collapse
|
2
|
Qin D, Wang R, Ji J, Wang D, Lu Y, Cao S, Chen Y, Wang L, Chen X, Zhang L. Hepatocyte-specific Sox9 knockout ameliorates acute liver injury by suppressing SHP signaling and improving mitochondrial function. Cell Biosci 2023; 13:159. [PMID: 37649095 PMCID: PMC10468867 DOI: 10.1186/s13578-023-01104-5] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2023] [Accepted: 08/09/2023] [Indexed: 09/01/2023] Open
Abstract
BACKGROUND AND AIMS Sex determining region Y related high-mobility group box protein 9 (Sox9) is expressed in a subset of hepatocytes, and it is important for chronic liver injury. However, the roles of Sox9+ hepatocytes in response to the acute liver injury and repair are poorly understood. METHODS In this study, we developed the mature hepatocyte-specific Sox9 knockout mouse line and applied three acute liver injury models including PHx, CCl4 and hepatic ischemia reperfusion (IR). Huh-7 cells were subjected to treatment with hydrogen peroxide (H2O2) in order to induce cellular damage in an in vitro setting. RESULTS We found the positive effect of Sox9 deletion on acute liver injury repair. Small heterodimer partner (SHP) expression was highly suppressed in hepatocyte-specific Sox9 deletion mouse liver, accompanied by less cell death and more cell proliferation. However, in mice with hepatocyte-specific Sox9 deletion and SHP overexpression, we observed an opposite phenotype. In addition, the overexpression of SOX9 in H2O2-treated Huh-7 cells resulted in an increase in cytoplasmic SHP accumulation, accompanied by a reduction of SHP in the nucleus. This led to impaired mitochondrial function and subsequent cell death. Notably, both the mitochondrial dysfunction and cell damage were reversed when SHP siRNA was employed, indicating the crucial role of SHP in mediating these effects. Furthermore, we found that Sox9, as a vital transcription factor, directly bound to SHP promoter to regulate SHP transcription. CONCLUSIONS Overall, our findings unravel the mechanism by which hepatocyte-specific Sox9 knockout ameliorates acute liver injury via suppressing SHP signaling and improving mitochondrial function. This study may provide a new treatment strategy for acute liver injury in future.
Collapse
Affiliation(s)
- Dan Qin
- College of Veterinary Medicine/College of Biomedicine and Health, Huazhong Agricultural University, Wuhan, 430070, Hubei, China
| | - Rui Wang
- College of Veterinary Medicine/College of Biomedicine and Health, Huazhong Agricultural University, Wuhan, 430070, Hubei, China
| | - Jinwei Ji
- College of Veterinary Medicine/College of Biomedicine and Health, Huazhong Agricultural University, Wuhan, 430070, Hubei, China
| | - Duo Wang
- College of Veterinary Medicine/College of Biomedicine and Health, Huazhong Agricultural University, Wuhan, 430070, Hubei, China
| | - Yuanyuan Lu
- College of Veterinary Medicine/College of Biomedicine and Health, Huazhong Agricultural University, Wuhan, 430070, Hubei, China
| | - Shiyao Cao
- College of Veterinary Medicine/College of Biomedicine and Health, Huazhong Agricultural University, Wuhan, 430070, Hubei, China
| | - Yaqing Chen
- College of Veterinary Medicine/College of Biomedicine and Health, Huazhong Agricultural University, Wuhan, 430070, Hubei, China
| | - Liqiang Wang
- Department of Nephrology, Chinese PLA General Hospital, Chinese PLA Institute of Nephrology, State Key Laboratory of Kidney Diseases, National Clinical Research Center for Kidney Diseases, 28th Fuxing Road, Beijing, 100853, China
| | - Xiangmei Chen
- Department of Nephrology, Chinese PLA General Hospital, Chinese PLA Institute of Nephrology, State Key Laboratory of Kidney Diseases, National Clinical Research Center for Kidney Diseases, 28th Fuxing Road, Beijing, 100853, China
| | - Lisheng Zhang
- College of Veterinary Medicine/College of Biomedicine and Health, Huazhong Agricultural University, Wuhan, 430070, Hubei, China.
| |
Collapse
|
3
|
Sakellakis M. Orphan receptors in prostate cancer. Prostate 2022; 82:1016-1024. [PMID: 35538397 DOI: 10.1002/pros.24370] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/07/2022] [Revised: 02/22/2022] [Accepted: 04/22/2022] [Indexed: 11/11/2022]
Abstract
BACKGROUND The identification of new cellular receptors has been increasing rapidly. A receptor is called "orphan" if an endogenous ligand has not been identified yet. METHODS Here we review receptors that contribute to prostate cancer and are considered orphan or partially orphan. This means that the full spectrum of their endogenous ligands remains unknown. RESULTS The orphan receptors are divided into two major families. The first group includes G protein-coupled receptors. Most are orphan olfactory receptors. OR51E1 inhibits cell proliferation and induces senescence in prostate cancer. OR51E2 inhibits prostate cancer growth, but promotes invasiveness and metastasis. GPR158, GPR110, and GPCR-X play significant roles in prostate cancer development and progression. However, GPR160 induces cell cycle arrest and apoptosis. The other major subset of orphan receptors are nuclear receptors. Receptor-related orphan receptor α (RORα) inhibits tumor growth, but RORγ stimulates androgen receptor signaling. PXR contributes to metabolic deactivation of androgens and inhibits cell proliferation. TLX has protumorigenic effects in prostate cancer, while its knockdown triggers cellular senescence and growth arrest. Estrogen-related receptor ERRγ can inhibit tumor growth but ERRα is protumorigenic. Dax1 and short heterodimeric partner are also inhibitory in prostate cancer. CONCLUSION There is a "zoo" of relatively underappreciated orphan receptors that play key roles in prostate cancer.
Collapse
Affiliation(s)
- Minas Sakellakis
- Fourth Oncology Department and Comprehensive Clinical Trials Center, Metropolitan Hospital, Athens, Greece
| |
Collapse
|
4
|
Wassel MMS, Ammar YA, Elhag Ali GAM, Belal A, Mehany ABM, Ragab A. Development of adamantane scaffold containing 1,3,4-thiadiazole derivatives: Design, synthesis, anti-proliferative activity and molecular docking study targeting EGFR. Bioorg Chem 2021; 110:104794. [PMID: 33735711 DOI: 10.1016/j.bioorg.2021.104794] [Citation(s) in RCA: 33] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2020] [Revised: 02/28/2021] [Accepted: 03/01/2021] [Indexed: 12/24/2022]
Abstract
A new series of 1,3,4-thiadiazolo-adamantane derivatives were synthesized through molecular hybridization approach, then used as starting material to synthesize chloro and cyano acetamide-thiadiazole derivatives 2, 3. The newly designed compounds 1-3 were treated with different reagents to design 5-adamantyl thiadiazole derivatives 4-17 and evaluate their in vitro anti-proliferative activity against three cancer cell lines (MCF-7, HepG-2 and A549). Doxorubicin was used as a positive control. The most promising compounds 5, 6, 10a, 10b, 14b, 14c, and 17 showed up-regulation for BAX and down-regulation of Bcl-2, these findings proved their role as hopeful apoptotic inducers. In addition, the inhibitory activity against both wild EGFRWT and mutant EGFRL858R-TK for these derivatives revealed that compounds 5, 14c, and 17 have IC50 value ranging from 85 nM to 71.5 nM against wild EGFRWT and 37.85-41.19 nM against the mutant type, Lapatinib was used as a reference standard with IC50 values of 31.8 nM and 39.53 nM, respectively. The most potent derivatives were subjected to further evaluation against double mutant EGFR L858R/T790M and showed good IC50 values between (0.27-0.78 nM) compared to Lapatinib (0.18 nM) and Erlotinib (0.21 nM). Among them, thiazolo-thiadiazole adamantane derivative 17 exhibited the strongest inhibitory activity to the EGFR. Molecular docking studies were performed inside the active site of EGFR (1M17), and binding energy scores ranged between (-19.19 to -22.07 Kcal/mol) compared to Erlotinib (-19.10 Kcal/mol). Furthermore, oral bioavailability beside some pharmacokinetics properties of these derivatives were also investigated in this research work.
Collapse
Affiliation(s)
- Mohammed M S Wassel
- Department of Foot and Mouth Disease, Veterinary Serum and Vaccine Research Institute (VSVRI), Abbasia, Cairo, Egypt
| | - Yousry A Ammar
- Chemistry Department, Faculty of Science, Al-Azhar University, Nasr City, 11884 Cairo, Egypt.
| | - Gameel A M Elhag Ali
- Chemistry Department, Faculty of Science, Al-Azhar University, Nasr City, 11884 Cairo, Egypt
| | - Amany Belal
- Department of Pharmaceutical Chemistry, College of Pharmacy, Taif University, P.O. Box 11099, Taif 21944, Saudi Arabia; Medicinal Chemistry Department, Faculty of Pharmacy, Beni-Suef University, Beni-Suef 62514, Egypt
| | - Ahmed B M Mehany
- Zoology Department, Faculty of Science, Al-Azhar University, Nasr City, Cairo, Egypt
| | - Ahmed Ragab
- Chemistry Department, Faculty of Science, Al-Azhar University, Nasr City, 11884 Cairo, Egypt.
| |
Collapse
|
5
|
Wang Y, Gao W, Li Y, Chow ST, Xie W, Zhang X, Zhou J, Chan FL. Interplay between orphan nuclear receptors and androgen receptor-dependent or-independent growth signalings in prostate cancer. Mol Aspects Med 2020; 78:100921. [PMID: 33121737 DOI: 10.1016/j.mam.2020.100921] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2020] [Revised: 10/08/2020] [Accepted: 10/15/2020] [Indexed: 12/14/2022]
Abstract
It is well-established that both the initial and advanced growth of prostate cancer depends critically on androgens and thus on the activated androgen receptor (AR) -mediated signaling pathway. The unique hormone-dependent feature of prostate cancer forms the biological basis of hormone or androgen-deprivation therapy (ADT) that aims to suppress the AR signaling by androgen depletion or AR antagonists. ADT still remains the mainstay treatment option for locally advanced or metastatic prostate cancer. However, most patients upon ADT will inevitably develop therapy-resistance and progress to relapse in the form of castration-resistant disease (castration-resistant prostate cancer or CRPC) or even a more aggressive androgen-independent subtype (therapy-related neuroendocrine prostate cancer or NEPC). Recent advances show that besides AR, some ligand-independent members of nuclear receptor superfamily-designated as orphan nuclear receptors (ONRs), as their endogenous physiological ligands are either absent or not yet identified to date, also play significant roles in the growth regulation of prostate cancer via multiple AR-dependent or -independent (AR-bypass) pathways or mechanisms. In this review, we summarize the recent progress in the newly elucidated roles of ONRs in prostate cancer, with a focus on their interplay in the AR-dependent pathways (intratumoral androgen biosynthesis and suppression of AR signaling) and AR-independent pathways or cellular processes (hypoxia, oncogene- or tumor suppressor-induced senescence, apoptosis and regulation of prostate cancer stem cells). These ONRs with their newly characterized roles not only can serve as novel biomarkers but also as potential therapeutic targets for management of advanced prostate cancer.
Collapse
Affiliation(s)
- Yuliang Wang
- School of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China.
| | - Weijie Gao
- School of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China
| | - Youjia Li
- School of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China
| | - Sin Ting Chow
- School of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China
| | - Wenjuan Xie
- School of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China
| | - Xingxing Zhang
- School of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China
| | - Jianfu Zhou
- School of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China; Department of Urology, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, 510370, China
| | - Franky Leung Chan
- School of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China.
| |
Collapse
|
6
|
Cincinelli R, Musso L, Guglielmi MB, La Porta I, Fucci A, Luca D'Andrea E, Cardile F, Colelli F, Signorino G, Darwiche N, Gervasoni S, Vistoli G, Pisano C, Dallavalle S. Novel adamantyl retinoid-related molecules with POLA1 inhibitory activity. Bioorg Chem 2020; 104:104253. [PMID: 32920362 DOI: 10.1016/j.bioorg.2020.104253] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2020] [Revised: 08/27/2020] [Accepted: 08/28/2020] [Indexed: 02/08/2023]
Abstract
Atypical retinoids (AR) or retinoid-related molecules (RRMs) represent a promising class of antitumor compounds. Among AR, E-3-(3'-adamantan-1-yl-4'-hydroxybiphenyl-4-yl)acrylic acid (adarotene), has been extensively investigated. In the present work we report the results of our efforts to develop new adarotene-related atypical retinoids endowed also with POLA1 inhibitory activity. The effects of the synthesized compounds on cell growth were determined on a panel of human and hematological cancer cell lines. The most promising compounds showed antitumor activity against several tumor histotypes and increased cytotoxic activity against an adarotene-resistant cell line, compared to the parent molecule. The antitumor activity of a selected compound was evaluated on HT-29 human colon carcinoma and human mesothelioma (MM487) xenografts. Particularly significant was the in vivo activity of the compound as a single agent compared to adarotene and cisplatin, against pleural mesothelioma MM487. No reduction of mice body weight was observed, thus suggesting a higher tolerability with respect to the parent compound adarotene.
Collapse
Affiliation(s)
- Raffaella Cincinelli
- Department of Food, Environmental and Nutritional Sciences, Università degli Studi di Milano, via Celoria 2, 20133 Milano, Italy
| | - Loana Musso
- Department of Food, Environmental and Nutritional Sciences, Università degli Studi di Milano, via Celoria 2, 20133 Milano, Italy
| | | | | | | | | | | | | | | | - Nadine Darwiche
- Department of Biochemistry and Molecular Genetics, Faculty of Medicine, American University of Beirut, Beirut, Lebanon
| | - Silvia Gervasoni
- Department of Pharmaceutical Sciences, Università degli Studi di Milano, via Mangiagalli 25, Milano 20133, Italy
| | - Giulio Vistoli
- Department of Pharmaceutical Sciences, Università degli Studi di Milano, via Mangiagalli 25, Milano 20133, Italy
| | - Claudio Pisano
- Biogem, Research Institute, Ariano Irpino, Avellino, Italy.
| | - Sabrina Dallavalle
- Department of Food, Environmental and Nutritional Sciences, Università degli Studi di Milano, via Celoria 2, 20133 Milano, Italy.
| |
Collapse
|
7
|
Reeves EK, Humke JN, Neufeldt SR. N-Heterocyclic Carbene Ligand-Controlled Chemodivergent Suzuki-Miyaura Cross Coupling. J Org Chem 2019; 84:11799-11812. [PMID: 31475828 DOI: 10.1021/acs.joc.9b01692] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
Two N-heterocyclic carbene ligands provide orthogonal chemoselectivity during the Pd-catalyzed Suzuki-Miyaura (SM) cross-coupling of chloroaryl triflates. The use of SIPr [SIPr = 1,3-bis(2,6-diisopropylphenyl)-4,5-dihydroimidazol-2-ylidene] leads to selective cross-coupling at chloride, while the use of SIMes [SIMes = 1,3-bis(2,4,6-trimethylphenyl)-4,5-dihydroimidazol-2-ylidene] provides selective coupling at triflate. With most chloroaryl triflates and arylboronic acids, ligand-controlled selectivity is high (≥10:1). The scope of this methodology is significantly more general than previously reported methods for selective SM coupling of chloroaryl triflates using phosphine ligands. Density functional theory studies suggest that palladium's ligation state during oxidative addition is different with SIMes compared to SIPr.
Collapse
Affiliation(s)
- Emily K Reeves
- Department of Chemistry and Biochemistry , Montana State University , Bozeman , Montana 59717 , United States
| | - Jenna N Humke
- Department of Chemistry and Biochemistry , Montana State University , Bozeman , Montana 59717 , United States
| | - Sharon R Neufeldt
- Department of Chemistry and Biochemistry , Montana State University , Bozeman , Montana 59717 , United States
| |
Collapse
|
8
|
Shiota M, Fujimoto N, Kashiwagi E, Eto M. The Role of Nuclear Receptors in Prostate Cancer. Cells 2019; 8:cells8060602. [PMID: 31212954 PMCID: PMC6627805 DOI: 10.3390/cells8060602] [Citation(s) in RCA: 26] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2019] [Revised: 06/12/2019] [Accepted: 06/13/2019] [Indexed: 12/12/2022] Open
Abstract
The nuclear receptor (NR) superfamily consists of 48 members that are divided into seven subfamilies. NRs are transcription factors that play an important role in a number of biological processes. The NR superfamily includes androgen receptor, which is a key player in prostate cancer pathogenesis, suggesting the functional roles of other NRs in prostate cancer. The findings on the roles of NRs in prostate cancer thus far have shown that several NRs such as vitamin D receptor, estrogen receptor β, and mineralocorticoid receptor play antioncogenic roles, while other NRs such as peroxisome proliferator-activated receptor γ and estrogen receptor α as well as androgen receptor play oncogenic roles. However, the roles of other NRs in prostate cancer remain controversial or uninvestigated. Further research on the role of NRs in prostate cancer is required and may lead to the development of novel preventions and therapeutics for prostate cancer.
Collapse
Affiliation(s)
- Masaki Shiota
- Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan.
| | - Naohiro Fujimoto
- Department of Urology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu 807-8555, Japan.
| | - Eiji Kashiwagi
- Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan.
| | - Masatoshi Eto
- Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan.
| |
Collapse
|
9
|
Kostrzewa T, Sahu KK, Gorska-Ponikowska M, Tuszynski JA, Kuban-Jankowska A. Synthesis of small peptide compounds, molecular docking, and inhibitory activity evaluation against phosphatases PTP1B and SHP2. DRUG DESIGN DEVELOPMENT AND THERAPY 2018; 12:4139-4147. [PMID: 30584278 PMCID: PMC6287413 DOI: 10.2147/dddt.s186614] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
Abstract
Background The protein tyrosine phosphatases PTP1B and SHP2 are promising drug targets in treatment design for breast cancer. Searching for specific inhibitors of their activity has recently become the challenge of many studies. Previous work has indicated that the promising PTP inhibitors may be small compounds that are able to bind and interact with amino residues from the binding site. Purpose The main goal of our study was to synthesize and analyze the effect of selected small peptide inhibitors on oncogenic PTP1B and SHP2 enzymatic activity and viability of MCF7 breast cancer cells. We also performed computational analysis of peptides binding with allosteric sites of PTP1B and SHP2 phosphatases. Methods We measured the inhibitory activity of compounds utilizing recombinant enzymes and MCF7 cell line. Computational analysis involved docking studies of binding conformation and interactions of inhibitors with allosteric sites of phosphatases. Results The results showed that the tested compounds decrease the enzymatic activity of phosphatases PTP1B and SHP2 with IC50 values in micromolar ranges. We observed higher inhibitory activity of dipeptides than tripeptides. Phe-Asp was the most effective against SHP2 enzymatic activity, with IC50=5.2±0.4 µM. Micromolar concentrations of tested dipeptides also decreased the viability of MCF7 breast cancer cells, with higher inhibitory activity observed for the Phe-Asp peptide. Moreover, the peptides tested were able to bind and interact with allosteric sites of PTP1B and SHP2 phosphatases. Conclusion Our research showed that small peptide compounds can be considered for the design of specific inhibitors of oncogenic protein tyrosine phosphatases.
Collapse
Affiliation(s)
- Tomasz Kostrzewa
- Department of Medical Chemistry, Medical University of Gdańsk, Gdańsk, Poland,
| | - Kamlesh K Sahu
- Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, AB, Canada
| | | | - Jack A Tuszynski
- Department of Oncology, University of Alberta, Edmonton, AB, Canada
| | | |
Collapse
|
10
|
Cariello M, Ducheix S, Maqdasy S, Baron S, Moschetta A, Lobaccaro JMA. LXRs, SHP, and FXR in Prostate Cancer: Enemies or Ménage à Quatre With AR? NUCLEAR RECEPTOR SIGNALING 2018; 15:1550762918801070. [PMID: 30718981 PMCID: PMC6348739 DOI: 10.1177/1550762918801070] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 06/20/2017] [Accepted: 01/03/2018] [Indexed: 12/11/2022]
Abstract
Androgens and androgen receptor (AR, NR3C4) clearly play a crucial role in
prostate cancer progression. Besides, the link between metabolic disorders and
the risk of developing a prostate cancer has been emerging these last years.
Interestingly, “lipid” nuclear receptors such as LXRα/NR1H3 and LXRβ/NR1H2 (as
well as FXRα/NR1H4 and SHP/NR0B2) have been described to decrease the lipid
metabolism, while AR increases it. Moreover, these former orphan nuclear
receptors can regulate androgen levels and modulate AR activity. Thus, it is not
surprising to find such receptors involved in the physiology of prostate. This
review is focused on the roles of liver X receptors (LXRs), farnesoid X receptor
(FXR), and small heterodimeric partner (SHP) in prostate physiology and their
capabilities to interfere with the androgen-regulated pathways by modulating the
levels of active androgen within the prostate. By the use of prostate cancer
cell lines, mice deficient for these nuclear receptors and human tissue
libraries, several authors have pointed out the putative possibility to
pharmacologically target these receptors. These data open a new field of
research for the development of new drugs that could overcome the castration
resistance in prostate cancer, a usual phenomenon in patients.
Collapse
Affiliation(s)
| | - Simon Ducheix
- Istituto Nazionale Biostrutture e Biosistemi, Roma, Italy
| | - Salwan Maqdasy
- Université Clermont Auvergne, Clermont-Ferrand, France.,Centre de Recherche en Nutrition Humaine d'Auvergne, Clermont-Ferrand, France.,CHU Clermont-Ferrand, France
| | - Silvère Baron
- Université Clermont Auvergne, Clermont-Ferrand, France.,Centre de Recherche en Nutrition Humaine d'Auvergne, Clermont-Ferrand, France
| | - Antonio Moschetta
- "Aldo Moro" University of Bari, Italy.,Istituto Nazionale Biostrutture e Biosistemi, Roma, Italy.,IRCCS Istituto Oncologico "Giovanni Paolo II," Bari, Italy
| | - Jean-Marc A Lobaccaro
- "Aldo Moro" University of Bari, Italy.,Istituto Nazionale Biostrutture e Biosistemi, Roma, Italy.,Université Clermont Auvergne, Clermont-Ferrand, France.,Centre de Recherche en Nutrition Humaine d'Auvergne, Clermont-Ferrand, France
| |
Collapse
|
11
|
Milošev MZ, Jakovljević K, Joksović MD, Stanojković T, Matić IZ, Perović M, Tešić V, Kanazir S, Mladenović M, Rodić MV, Leovac VM, Trifunović S, Marković V. Mannich bases of 1,2,4-triazole-3-thione containing adamantane moiety: Synthesis, preliminary anticancer evaluation, and molecular modeling studies. Chem Biol Drug Des 2017; 89:943-952. [PMID: 27933733 DOI: 10.1111/cbdd.12920] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2016] [Revised: 11/08/2016] [Accepted: 11/21/2016] [Indexed: 12/22/2022]
Abstract
A series of 18 novel N-Mannich bases derived from 5-adamantyl-1,2,4-triazole-3-thione was synthesized and characterized using NMR spectroscopy and X-ray diffraction technique. All derivatives were evaluated for their anticancer potential against four human cancer cell lines. Several tested compounds exerted good cytotoxic activities on K562 and HL-60 cell lines, along with pronounced selectivity, showing lower cytotoxicity against normal fibroblasts MRC-5 compared to cancer cells. The effects of compounds 5b, 5e, and 5j on the cell cycle were investigated by flow cytometric analysis. It was found that these compounds cause the accumulation of cells in the subG1 and G1 phases of the cell cycle and induce caspase-dependent apoptosis, while the anti-angiogenic effects of 5b, 5e, and 5j have been confirmed in EA.hy926 cells using a tube formation assay. Further, the interaction of Bax protein with compound 5b was investigated by means of molecular modeling, applying the combined molecular docking/molecular dynamics approach.
Collapse
Affiliation(s)
- Milorad Z Milošev
- Faculty of Medicinal Science, University of Kragujevac, Kragujevac, Serbia
| | - Katarina Jakovljević
- Faculty of Science, Department of Chemistry, University of Kragujevac, Kragujevac, Serbia
| | - Milan D Joksović
- Faculty of Science, Department of Chemistry, University of Kragujevac, Kragujevac, Serbia
| | | | - Ivana Z Matić
- Institute of Oncology and Radiology of Serbia, Belgrade, Serbia
| | - Milka Perović
- Institute for Biological Research "Siniša Stanković", Department of Neurobiology, University of Belgrade, Belgrade, Serbia
| | - Vesna Tešić
- Institute for Biological Research "Siniša Stanković", Department of Neurobiology, University of Belgrade, Belgrade, Serbia
| | - Selma Kanazir
- Institute for Biological Research "Siniša Stanković", Department of Neurobiology, University of Belgrade, Belgrade, Serbia
| | - Milan Mladenović
- Faculty of Science, Department of Chemistry, University of Kragujevac, Kragujevac, Serbia
| | - Marko V Rodić
- Faculty of Sciences, University of Novi Sad, Novi Sad, Serbia
| | | | | | - Violeta Marković
- Faculty of Science, Department of Chemistry, University of Kragujevac, Kragujevac, Serbia
| |
Collapse
|
12
|
Decoding the role of the nuclear receptor SHP in regulating hepatic stellate cells and liver fibrogenesis. Sci Rep 2017; 7:41055. [PMID: 28117422 PMCID: PMC5259793 DOI: 10.1038/srep41055] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2016] [Accepted: 12/16/2016] [Indexed: 12/13/2022] Open
Abstract
The small heterodimer partner (SHP) is an orphan nuclear receptor that lacks the DNA binding domain while conserves a putative ligand-binding site, thought that endogenous ligands for this receptor are unknown. Previous studies have determined that SHP activation protects against development of liver fibrosis a process driven by trans-differentiation and activation of hepatic stellate cells (HSCs), a miofibroblast like cell type, involved in extracellular matrix (ECM) deposition. To dissect signals involved in this activity we generated SHP-overexpressing human and rat HSCs. Forced expression of SHP in HSC-T6 altered the expression of 574 genes. By pathway and functional enrichment analyses we detected a cluster of 46 differentially expressed genes involved in HSCs trans-differentiation. Using a isoxazole scaffold we designed and synthesized a series of SHP agonists. The most potent member of this group, ISO-COOH (EC50: 9 μM), attenuated HSCs trans-differentiation and ECM deposition in vitro, while in mice rendered cirrhotic by carbon tetrachloride (CCl4) or α-naphthyl-isothiocyanate (ANIT), protected against development of liver fibrosis as measured by morphometric analysis and expression of α-SMA and α1-collagen mRNAs. In aggregate, present results identify SHP as a counter-regulatory signal for HSCs transactivation and describe a novel class of SHP agonists endowed with anti-fibrotic activity.
Collapse
|
13
|
Leach DA, Powell SM, Bevan CL. WOMEN IN CANCER THEMATIC REVIEW: New roles for nuclear receptors in prostate cancer. Endocr Relat Cancer 2016; 23:T85-T108. [PMID: 27645052 DOI: 10.1530/erc-16-0319] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/12/2016] [Accepted: 09/19/2016] [Indexed: 12/20/2022]
Abstract
Prostate cancer has, for decades, been treated by inhibiting androgen signalling. This is effective in the majority of patients, but inevitably resistance develops and patients progress to life-threatening metastatic disease - hence the quest for new effective therapies for 'castrate-resistant' prostate cancer (CRPC). Studies into what pathways can drive tumour recurrence under these conditions has identified several other nuclear receptor signalling pathways as potential drivers or modulators of CRPC.The nuclear receptors constitute a large (48 members) superfamily of transcription factors sharing a common modular functional structure. Many of them are activated by the binding of small lipophilic molecules, making them potentially druggable. Even those for which no ligand exists or has yet been identified may be tractable to activity modulation by small molecules. Moreover, genomic studies have shown that in models of CRPC, other nuclear receptors can potentially drive similar transcriptional responses to the androgen receptor, while analysis of expression and sequencing databases shows disproportionately high mutation and copy number variation rates among the superfamily. Hence, the nuclear receptor superfamily is of intense interest in the drive to understand how prostate cancer recurs and how we may best treat such recurrent disease. This review aims to provide a snapshot of the current knowledge of the roles of different nuclear receptors in prostate cancer - a rapidly evolving field of research.
Collapse
Affiliation(s)
- Damien A Leach
- Division of CancerImperial Centre for Translational & Experimental Medicine, Imperial, College London, Hammersmith Hospital Campus, London, UK
| | - Sue M Powell
- Division of CancerImperial Centre for Translational & Experimental Medicine, Imperial, College London, Hammersmith Hospital Campus, London, UK
| | - Charlotte L Bevan
- Division of CancerImperial Centre for Translational & Experimental Medicine, Imperial, College London, Hammersmith Hospital Campus, London, UK
| |
Collapse
|
14
|
Wu D, Cheung A, Wang Y, Yu S, Chan FL. The emerging roles of orphan nuclear receptors in prostate cancer. BIOCHIMICA ET BIOPHYSICA ACTA 2016; 1866:23-36. [PMID: 27264242 DOI: 10.1016/j.bbcan.2016.06.001] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/01/2015] [Revised: 05/31/2016] [Accepted: 06/01/2016] [Indexed: 12/25/2022]
Abstract
Orphan nuclear receptors are members of the nuclear receptor (NR) superfamily and are so named because their endogenous physiological ligands are either unknown or may not exist. Because of their important regulatory roles in many key physiological processes, dysregulation of signalings controlled by these receptors is associated with many diseases including cancer. Over years, studies of orphan NRs have become an area of great interest because their specific physiological and pathological roles have not been well-defined, and some of them are promising drug targets for diseases. The recently identified synthetic small molecule ligands, acting as agonists or antagonists, to these orphan NRs not only help to understand better their functional roles but also highlight that the signalings mediated by these ligand-independent NRs in diseases could be therapeutically intervened. This review is a summary of the recent advances in elucidating the emerging functional roles of orphan NRs in cancers, especially prostate cancer. In particular, some orphan NRs, RORγ, TR2, TR4, COUP-IFII, ERRα, DAX1 and SHP, exhibit crosstalk or interference with androgen receptor (AR) signaling in either normal or malignant prostatic cells, highlighting their involvement in prostate cancer progression as androgen and AR signaling pathway play critical roles in this process. We also propose that a better understanding of the mechanism of actions of these orphan NRs in prostate gland or prostate cancer could help to evaluate their potential value as therapeutic targets for prostate cancer.
Collapse
Affiliation(s)
- Dinglan Wu
- School of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong, China
| | - Alyson Cheung
- School of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong, China
| | - Yuliang Wang
- School of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong, China
| | - Shan Yu
- School of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong, China.
| | - Franky L Chan
- School of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong, China.
| |
Collapse
|
15
|
Sun J, Wang S, Bu W, Wei MY, Li WW, Yao MN, Ma ZY, Lu CT, Li HH, Hu NP, Zhang EH, Yang GD, Wen AD, Zhu XH. Synthesis of a novel adamantyl nitroxide derivative with potent anti-hepatoma activity in vitro and in vivo. Am J Cancer Res 2016; 6:1271-1286. [PMID: 27429843 PMCID: PMC4937732] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2016] [Accepted: 05/16/2016] [Indexed: 06/06/2023] Open
Abstract
In this study, a novel adamantyl nitroxide derivative was synthesized and its antitumor activities in vitro and in vivo were investigated. The adamantyl nitroxide derivative 4 displayed a potent anticancer activity against all the tested human hepatoma cells, especially with IC50 of 68.1 μM in Bel-7404 cells, compared to the positive control 5-FU (IC50=607.7 μM). The significant inhibition of cell growth was also observed in xenograft mouse model, with low toxicity. Compound 4 suppressed the cell migration and invasion, induced the G2/M phase arrest. Further mechanistic studies revealed that compound 4 induced cell death, which was accompanied with damaging mitochondria, increasing the generation of intracellular reactive oxygen species, cleavages of caspase-9 and caspase-3, as well as activations of Bax and Bcl-2. These results confirmed that adamantyl nitroxide derivative exhibited selective antitumor activities via mitochondrial apoptosis pathway in Bel-7404 cells, and would be a potential anticancer agent for liver cancer.
Collapse
Affiliation(s)
- Jin Sun
- Department of Pharmacy, Xijing Hospital, Fourth Military Medical UniversityXi’an, Shaanxi 710032, China
- College of Pharmacy, Shaanxi University of Chinese MedicineXianyang, Shaanxi 712046, China
| | - Shan Wang
- Department of Pharmacy, Xijing Hospital, Fourth Military Medical UniversityXi’an, Shaanxi 710032, China
| | - Wei Bu
- Department of Pharmacy, Xijing Hospital, Fourth Military Medical UniversityXi’an, Shaanxi 710032, China
| | - Meng-Ying Wei
- State Key Laboratory of Cancer Biology, Department of Biochemistry and Molecular Biology, Fourth Military Medical UniversityXi’an, Shaanxi 710032, China
| | - Wei-Wei Li
- Department of Pharmacy, Xijing Hospital, Fourth Military Medical UniversityXi’an, Shaanxi 710032, China
| | - Min-Na Yao
- Department of Pharmacy, Xijing Hospital, Fourth Military Medical UniversityXi’an, Shaanxi 710032, China
| | - Zhong-Ying Ma
- Department of Pharmacy, Xijing Hospital, Fourth Military Medical UniversityXi’an, Shaanxi 710032, China
| | - Cheng-Tao Lu
- Department of Pharmacy, Xijing Hospital, Fourth Military Medical UniversityXi’an, Shaanxi 710032, China
| | - Hui-Hui Li
- College of Pharmacy, Shaanxi University of Chinese MedicineXianyang, Shaanxi 712046, China
| | - Na-Ping Hu
- College of Pharmacy, Shaanxi University of Chinese MedicineXianyang, Shaanxi 712046, China
| | - En-Hu Zhang
- College of Pharmacy, Shaanxi University of Chinese MedicineXianyang, Shaanxi 712046, China
| | - Guo-Dong Yang
- State Key Laboratory of Cancer Biology, Department of Biochemistry and Molecular Biology, Fourth Military Medical UniversityXi’an, Shaanxi 710032, China
| | - Ai-Dong Wen
- Department of Pharmacy, Xijing Hospital, Fourth Military Medical UniversityXi’an, Shaanxi 710032, China
| | - Xiao-He Zhu
- Department of Pharmacy, Xijing Hospital, Fourth Military Medical UniversityXi’an, Shaanxi 710032, China
| |
Collapse
|
16
|
Zhu XH, Sun J, Wang S, Bu W, Yao MN, Gao K, Song Y, Zhao JY, Lu CT, Zhang EH, Yang ZF, Wen AD. Synthesis, crystal structure, superoxide scavenging activity, anticancer and docking studies of novel adamantyl nitroxide derivatives. J Mol Struct 2016. [DOI: 10.1016/j.molstruc.2015.12.048] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
17
|
Safe S, Jin UH, Morpurgo B, Abudayyeh A, Singh M, Tjalkens RB. Nuclear receptor 4A (NR4A) family - orphans no more. J Steroid Biochem Mol Biol 2016; 157:48-60. [PMID: 25917081 PMCID: PMC4618773 DOI: 10.1016/j.jsbmb.2015.04.016] [Citation(s) in RCA: 129] [Impact Index Per Article: 16.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/15/2015] [Revised: 03/26/2015] [Accepted: 04/21/2015] [Indexed: 01/17/2023]
Abstract
The orphan nuclear receptors NR4A1, NR4A2 and NR4A3 are immediate early genes induced by multiple stressors, and the NR4A receptors play an important role in maintaining cellular homeostasis and disease. There is increasing evidence for the role of these receptors in metabolic, cardiovascular and neurological functions and also in inflammation and inflammatory diseases and in immune functions and cancer. Despite the similarities of NR4A1, NR4A2 and NR4A3 and their interactions with common cis-genomic elements, they exhibit unique activities and cell-/tissue-specific functions. Although endogenous ligands for NR4A receptors have not been identified, there is increasing evidence that structurally-diverse synthetic molecules can directly interact with the ligand binding domain of NR4A1 and act as agonists or antagonists, and ligands for NR4A2 and NR4A3 have also been identified. Since NR4A receptors are key factors in multiple diseases, there are opportunities for the future development of NR4A ligands for clinical applications in treating multiple health problems including metabolic, neurologic and cardiovascular diseases, other inflammatory conditions, and cancer.
Collapse
MESH Headings
- Arthritis/metabolism
- Cardiovascular Diseases/metabolism
- DNA-Binding Proteins/metabolism
- Homeostasis
- Humans
- Immunity, Cellular
- Inflammation/metabolism
- Ligands
- Metabolic Diseases/genetics
- Metabolic Diseases/metabolism
- Neoplasms/metabolism
- Nuclear Receptor Subfamily 4, Group A, Member 1/genetics
- Nuclear Receptor Subfamily 4, Group A, Member 1/metabolism
- Nuclear Receptor Subfamily 4, Group A, Member 2/genetics
- Nuclear Receptor Subfamily 4, Group A, Member 2/metabolism
- Receptors, Steroid/metabolism
- Receptors, Thyroid Hormone/metabolism
Collapse
Affiliation(s)
- Stephen Safe
- Department of Veterinary Physiology and Pharmacology, College of Veterinary Medicine, Texas A&M University, College Station, TX 77843, USA.
| | - Un-Ho Jin
- Department of Veterinary Physiology and Pharmacology, College of Veterinary Medicine, Texas A&M University, College Station, TX 77843, USA
| | - Benjamin Morpurgo
- Texas A&M Institute for Genomic Medicine, Texas A&M University, 670 Raymond Stotzer Pkwy, College Station, TX 77843, USA
| | - Ala Abudayyeh
- Department of General Internal Medicine, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
| | - Mandip Singh
- Department of Pharmaceutics, College of Pharmacy and Pharmaceutical Sciences, Florida A&M University, Tallahassee, FL 32307, USA
| | - Ronald B Tjalkens
- Department of Toxicology and Neuroscience, Colorado State University, 1680Campus Delivery, Fort Collins, CO 80523-1680, USA
| |
Collapse
|
18
|
Zhi X, Zhou XE, Melcher K, Xu HE. Structures and regulation of non-X orphan nuclear receptors: A retinoid hypothesis. J Steroid Biochem Mol Biol 2016; 157:27-40. [PMID: 26159912 DOI: 10.1016/j.jsbmb.2015.06.012] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/21/2015] [Revised: 06/10/2015] [Accepted: 06/16/2015] [Indexed: 12/28/2022]
Abstract
Nuclear receptors are defined as a family of ligand regulated transcription factors [1-6]. While this definition reflects that ligand binding is a key property of nuclear receptors, it is still a heated subject of debate if all the nuclear receptors (48 human members) can bind ligands (ligands referred here to both physiological and synthetic ligands). Recent studies in nuclear receptor structure biology and pharmacology have undoubtedly increased our knowledge of nuclear receptor functions and their regulation. As a result, they point to new avenues for the discovery and development of nuclear receptor regulators, including nuclear receptor ligands. Here we review the recent literature on orphan nuclear receptor structural analysis and ligand identification, particularly on the orphan nuclear receptors that do not heterodimerize with retinoid X receptors, which we term as non-X orphan receptors. We also propose a speculative "retinoid hypothesis" for a subset of non-X orphan nuclear receptors, which we hope to help shed light on orphan nuclear receptor biology and drug discovery. This article is part of a Special Issue entitled 'Orphan Nuclear Receptors'.
Collapse
Affiliation(s)
- Xiaoyong Zhi
- Laboratory of Structural Sciences, Van Andel Research Institute, 333 Bostwick Ave., N.E., Grand Rapids, MI 49503, USA; Autophagy Research Center, University of Texas Southwestern Medical Center, 6000Harry Hines Blvd., Dallas, TX 75390, USA.
| | - X Edward Zhou
- Laboratory of Structural Sciences, Van Andel Research Institute, 333 Bostwick Ave., N.E., Grand Rapids, MI 49503, USA
| | - Karsten Melcher
- Laboratory of Structural Sciences, Van Andel Research Institute, 333 Bostwick Ave., N.E., Grand Rapids, MI 49503, USA
| | - H Eric Xu
- Laboratory of Structural Sciences, Van Andel Research Institute, 333 Bostwick Ave., N.E., Grand Rapids, MI 49503, USA; VARI-SIMM Center, Key Laboratory of Receptor Research, Shanghai Institute of MateriaMedica, Chinese Academy of Sciences, Shanghai 201203, China.
| |
Collapse
|
19
|
Aesoy R, Clyne CD, Chand AL. Insights into Orphan Nuclear Receptors as Prognostic Markers and Novel Therapeutic Targets for Breast Cancer. Front Endocrinol (Lausanne) 2015; 6:115. [PMID: 26300846 PMCID: PMC4528200 DOI: 10.3389/fendo.2015.00115] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/04/2015] [Accepted: 07/11/2015] [Indexed: 12/11/2022] Open
Abstract
There is emerging evidence asserting the importance of orphan nuclear receptors (ONRs) in cancer initiation and progression. In breast cancer, there is a lot unknown about ONRs in terms of their expression profile and their transcriptional targets in the various stages of tumor progression. With the classification of breast tumors into distinct molecular subtypes, we assess ONR expression in the different breast cancer subtypes and with patient outcomes. Complementing this, we review evidence implicating ONR-dependent molecular pathways in breast cancer progression to identify candidate ONRs as potential prognostic markers and/or as therapeutic targets.
Collapse
Affiliation(s)
- Reidun Aesoy
- Cancer Drug Discovery, Hudson Institute of Medical Research, Melbourne, VIC, Australia
- Department of Biomedicine, University of Bergen, Bergen, Norway
| | - Colin D. Clyne
- Cancer Drug Discovery, Hudson Institute of Medical Research, Melbourne, VIC, Australia
- Department of Molecular and Translational Science, Monash University, Clayton, VIC, Australia
| | - Ashwini L. Chand
- Cancer Drug Discovery, Hudson Institute of Medical Research, Melbourne, VIC, Australia
- Cancer and Inflammation Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne, VIC, Australia
- School of Cancer Medicine, La Trobe University, Melbourne, VIC, Australia
- *Correspondence: Ashwini L. Chand,
| |
Collapse
|
20
|
García-Rodríguez J, Pérez-Rodríguez S, Ortiz MA, Pereira R, de Lera AR, Piedrafita FJ. Inhibition of IκB kinase-β and IκB kinase-α by heterocyclic adamantyl arotinoids. Bioorg Med Chem 2014; 22:1285-302. [PMID: 24457093 DOI: 10.1016/j.bmc.2014.01.006] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2013] [Revised: 11/26/2013] [Accepted: 01/03/2014] [Indexed: 12/18/2022]
Abstract
We recently reported on a series of retinoid-related molecules containing an adamantyl group, a.k.a. adamantyl arotinoids (AdArs), that showed significant cancer cell growth inhibitory activity and activated RXRα (NR2B1) in transient transfection assays while devoid of RAR transactivation capacity. We have now explored whether these AdArs could also bind and inhibit IKKβ, a known target that mediates the induction of apoptosis and cancer cell growth inhibition by related AdArs containing a chalcone functional group. In addition, we have prepared and evaluated novel AdArs that incorporate a central heterocyclic ring connecting the adamantyl-phenol and the carboxylic acid at the polar termini. Our results indicate that the majority of the RXRα activating compounds lacked IKKβ inhibitory activity. In contrast, the novel heterocyclic AdArs containing a thiazole or pyrazine ring linked to a benzoic acid motif were potent inhibitors of both IKKα and IKKβ, which in most cases paralleled significant growth inhibitory and apoptosis inducing activities.
Collapse
Affiliation(s)
- José García-Rodríguez
- Departamento de Química Orgánica, CINBIO and Instituto de Investigación Biomédica de Vigo (IBIV), Universidade de Vigo, Lagoas-Marcosende, 36310 Vigo, Spain
| | - Santiago Pérez-Rodríguez
- Departamento de Química Orgánica, CINBIO and Instituto de Investigación Biomédica de Vigo (IBIV), Universidade de Vigo, Lagoas-Marcosende, 36310 Vigo, Spain
| | - María A Ortiz
- Torrey Pines Institute for Molecular Studies, 3550 General Atomics Ct, San Diego, CA 92121, USA
| | - Raquel Pereira
- Departamento de Química Orgánica, CINBIO and Instituto de Investigación Biomédica de Vigo (IBIV), Universidade de Vigo, Lagoas-Marcosende, 36310 Vigo, Spain
| | - Angel R de Lera
- Departamento de Química Orgánica, CINBIO and Instituto de Investigación Biomédica de Vigo (IBIV), Universidade de Vigo, Lagoas-Marcosende, 36310 Vigo, Spain.
| | - F Javier Piedrafita
- Torrey Pines Institute for Molecular Studies, 3550 General Atomics Ct, San Diego, CA 92121, USA.
| |
Collapse
|
21
|
Structural insights into gene repression by the orphan nuclear receptor SHP. Proc Natl Acad Sci U S A 2013; 111:839-44. [PMID: 24379397 DOI: 10.1073/pnas.1322827111] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023] Open
Abstract
Small heterodimer partner (SHP) is an orphan nuclear receptor that functions as a transcriptional repressor to regulate bile acid and cholesterol homeostasis. Although the precise mechanism whereby SHP represses transcription is not known, E1A-like inhibitor of differentiation (EID1) was isolated as a SHP-interacting protein and implicated in SHP repression. Here we present the crystal structure of SHP in complex with EID1, which reveals an unexpected EID1-binding site on SHP. Unlike the classical cofactor-binding site near the C-terminal helix H12, the EID1-binding site is located at the N terminus of the receptor, where EID1 mimics helix H1 of the nuclear receptor ligand-binding domain. The residues composing the SHP-EID1 interface are highly conserved. Their mutation diminishes SHP-EID1 interactions and affects SHP repressor activity. Together, these results provide important structural insights into SHP cofactor recruitment and repressor function and reveal a conserved protein interface that is likely to have broad implications for transcriptional repression by orphan nuclear receptors.
Collapse
|
22
|
Safe S, Jin UH, Hedrick E, Reeder A, Lee SO. Minireview: role of orphan nuclear receptors in cancer and potential as drug targets. Mol Endocrinol 2013; 28:157-72. [PMID: 24295738 DOI: 10.1210/me.2013-1291] [Citation(s) in RCA: 115] [Impact Index Per Article: 10.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023] Open
Abstract
The nuclear orphan receptors for which endogenous ligands have not been identified include nuclear receptor (NR)0B1 (adrenal hypoplasia congenita critical region on chromosome X gene), NR0B2 (small heterodimer partner), NR1D1/2 (Rev-Erbα/β), NR2C1 (testicular receptor 2), NR2C2 (testicular receptor 4), NR2E1 (tailless), NR2E3 (photoreceptor-specific NR [PNR]), NR2F1 chicken ovalbumin upstream promoter transcription factor 1 (COUP-TFI), NR2F2 (COUP-TFII), NR2F6 (v-erbA-related protein), NR4A1 (Nur77), NR4A2 (Nurr1), NR4A3 (Nor1), and NR6A1 (GCNF). These receptors play essential roles in development, cellular homeostasis, and disease including cancer where over- or underexpression of some receptors has prognostic significance for patient survival. Results of receptor knockdown or overexpression in vivo and in cancer cell lines demonstrate that orphan receptors exhibit tumor-specific pro-oncogenic or tumor suppressor-like activity. For example, COUP-TFII expression is both a positive (ovarian) and negative (prostate and breast) prognostic factor for cancer patients; in contrast, the prognostic activity of adrenal hypoplasia congenita critical region on chromosome X gene for the same tumors is the inverse of COUP-TFII. Functional studies show that Nur77 is tumor suppressor like in acute leukemia, whereas silencing Nur77 in pancreatic, colon, lung, lymphoma, melanoma, cervical, ovarian, gastric, and some breast cancer cell lines induces one or more of several responses including growth inhibition and decreased survival, migration, and invasion. Although endogenous ligands for the orphan receptors have not been identified, there is increasing evidence that different structural classes of compounds activate, inactivate, and directly bind several orphan receptors. Thus, the screening and development of selective orphan receptor modulators will have important clinical applications as novel mechanism-based agents for treating cancer patients overexpressing one or more orphan receptors and also for combined drug therapies.
Collapse
Affiliation(s)
- Stephen Safe
- Department of Veterinary Physiology and Pharmacology (S.S., E.H., A.R.), Texas A&M University, College Station, Texas 77808; and Institute of Biosciences and Technology (S.S., U.-H.J., S.-O.L.), Texas A&M Health Science Center, Houston, Texas 77030
| | | | | | | | | |
Collapse
|
23
|
Lorenzo P, Ortiz MA, Álvarez R, Piedrafita FJ, de Lera ÁR. Adamantyl arotinoids that inhibit IκB kinase α and IκB kinase β. ChemMedChem 2013; 8:1184-98. [PMID: 23653373 PMCID: PMC3892996 DOI: 10.1002/cmdc.201300100] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2013] [Revised: 04/15/2013] [Indexed: 12/14/2022]
Abstract
A series of analogues of the adamantyl arotinoid (AdAr) chalcone MX781 with halogenated benzyloxy substituents at C2' and heterocyclic derivatives replacing the chalcone group were found to inhibit IκBα kinase α (IKKα) and IκBα kinase β (IKKβ) activities. The growth inhibitory capacity of some analogues against Jurkat T cells as well as prostate carcinoma (PC-3) and chronic myelogenous leukemia (K562) cells, which contain elevated basal IKK activity, correlates with the induction of apoptosis and increased inhibition of recombinant IKKα and IKKβ in vitro, pointing toward inhibition of IKK/NFκB signaling as the most likely target of the anticancer activities of these AdArs. While the chalcone functional group present in many dietary compounds has been shown to mediate interactions with IKKβ via Michael addition with cysteine residues, AdArs containing a five-membered heterocyclic ring (isoxazoles and pyrazoles) in place of the chalcone of the parent system are potent inhibitors of IKKs as well, which suggests that other mechanisms for inhibition exist that do not depend on the presence of a reactive α,β-unsaturated ketone.
Collapse
Affiliation(s)
- Paula Lorenzo
- Departamento de Química Orgánica e Instituto de Investigaciones, Biomédicas de Vigo (IBIV), Universidade de Vigo, Lagoas-Marcosende, 36310 Vigo (Spain), Fax: (+34)986811940
| | - María A. Ortiz
- Torrey Pines Institute for Molecular Studies, 3550 General Stomics Ct., San Diego, CA 92121, Fax: (+1) 858 5973884
| | - Rosana Álvarez
- Departamento de Química Orgánica e Instituto de Investigaciones, Biomédicas de Vigo (IBIV), Universidade de Vigo, Lagoas-Marcosende, 36310 Vigo (Spain), Fax: (+34)986811940
| | - F. Javier Piedrafita
- Torrey Pines Institute for Molecular Studies, 3550 General Stomics Ct., San Diego, CA 92121, Fax: (+1) 858 5973884
| | - Ángel R. de Lera
- Departamento de Química Orgánica e Instituto de Investigaciones, Biomédicas de Vigo (IBIV), Universidade de Vigo, Lagoas-Marcosende, 36310 Vigo (Spain), Fax: (+34)986811940
| |
Collapse
|
24
|
Wanka L, Iqbal K, Schreiner PR. The lipophilic bullet hits the targets: medicinal chemistry of adamantane derivatives. Chem Rev 2013; 113:3516-604. [PMID: 23432396 PMCID: PMC3650105 DOI: 10.1021/cr100264t] [Citation(s) in RCA: 441] [Impact Index Per Article: 40.1] [Reference Citation Analysis] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Affiliation(s)
- Lukas Wanka
- Institute of Organic Chemistry, Justus-Liebig University Giessen, Heinrich-Buff-Ring 58, 35392 Giessen, Germany; Fax +49(641)9934309
- Department of Neurochemistry, New York State Institute for Basic Research in Developmental Disabilities, 1050 Forest Hill Road, Staten Island, NY 10314-6399, USA
| | - Khalid Iqbal
- Department of Neurochemistry, New York State Institute for Basic Research in Developmental Disabilities, 1050 Forest Hill Road, Staten Island, NY 10314-6399, USA
| | - Peter R. Schreiner
- Institute of Organic Chemistry, Justus-Liebig University Giessen, Heinrich-Buff-Ring 58, 35392 Giessen, Germany; Fax +49(641)9934309
| |
Collapse
|
25
|
Baptissart M, Vega A, Maqdasy S, Caira F, Baron S, Lobaccaro JMA, Volle DH. Bile acids: from digestion to cancers. Biochimie 2012; 95:504-17. [PMID: 22766017 DOI: 10.1016/j.biochi.2012.06.022] [Citation(s) in RCA: 82] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2012] [Accepted: 06/21/2012] [Indexed: 02/07/2023]
Abstract
Bile acids (BAs) are cholesterol metabolites that have been extensively studied these last decades. BAs have been classified in two groups. Primary BAs are synthesized in liver, when secondary BAs are produced by intestinal bacteria. Recently, next to their ancestral roles in digestion and fat solubilization, BAs have been described as signaling molecules involved in many physiological functions, such as glucose and energy metabolisms. These signaling pathways involve the activation of the nuclear receptor FXRα or of the G-protein-coupled receptor TGR5. These two receptors have selective affinity to different types of BAs and show different expression patterns, leading to different described roles of BAs. It has been suggested for long that BAs could be molecules linked to tumor processes. Indeed, as many other molecules, regarding analyzed tissues, BAs could have either protective or pro-carcinogen activities. However, the molecular mechanisms responsible for these effects have not been characterized yet. It involves either chemical properties or their capacities to activate their specific receptors FXRα or TGR5. This review highlights and discusses the potential links between BAs and cancer diseases and the perspectives of using BAs as potential therapeutic targets in several pathologies.
Collapse
Affiliation(s)
- Marine Baptissart
- INSERM U 1103, Génétique Reproduction et Développement, Aubiere, France
| | | | | | | | | | | | | |
Collapse
|
26
|
Zhang Y, Gong W, Dai S, Huang G, Shen X, Gao M, Xu Z, Zeng Y, He F. Downregulation of human farnesoid X receptor by miR-421 promotes proliferation and migration of hepatocellular carcinoma cells. Mol Cancer Res 2012; 10:516-22. [PMID: 22446874 DOI: 10.1158/1541-7786.mcr-11-0473] [Citation(s) in RCA: 67] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
The farnesoid X receptor (FXR) is a member of the nuclear receptor superfamily that is highly expressed in liver, kidney, adrenal gland, and intestine. It plays an important role in regulating the progression of several cancers including hepatocellular carcinoma (HCC). So it is necessary to study the regulation of FXR. In this study, we found that the expression of miR-421 was inversely correlated with FXR protein level in HCC cell lines. Treatment with miR-421 mimic repressed FXR translation. The reporter assay revealed that miR-421 targeted 3' untranslated region of human FXR mRNA. Furthermore, downregulation of FXR by miR-421 promoted the proliferation, migration, and invasion of HCC cells. These results suggest that miR-421 may serve as a novel molecular target for manipulating FXR expression in hepatocyte and for the treatment of HCC.
Collapse
Affiliation(s)
- Yan Zhang
- Department of Biochemistry and Molecular Biology, College of Basic Medical Sciences, Third Military Medical University, Chongqing 400038, China
| | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Wang N, Wang R, Shi X, Zou G. Ion-exchange-resin-catalyzed adamantylation of phenol derivatives with adamantanols: Developing a clean process for synthesis of 2-(1-adamantyl)-4-bromophenol, a key intermediate of adapalene. Beilstein J Org Chem 2012; 8:227-33. [PMID: 22423289 PMCID: PMC3302083 DOI: 10.3762/bjoc.8.23] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2011] [Accepted: 01/26/2012] [Indexed: 12/18/2022] Open
Abstract
A clean process has been developed for the synthesis of 2-adamantylphenol derivatives through adamantylation of substituted phenols with adamantanols catalyzed by commercially available and recyclable ion-exchange sulfonic acid resin in acetic acid. The sole byproduct of the adamantylation reaction, namely water, could be converted into the solvent acetic acid by addition of a slight excess of acetic anhydride during the work-up procedure, making the process waste-free except for regeneration of the ion-exchange resin, and facilitating the recycling of the resin catalyst. The ion-exchange sulfonic acid resin catalyst could be readily recycled by filtration and directly reused at least ten times without a significant loss of activity. The key intermediate of adapalene, 2-(1-adamantyl)-4-bromophenol, could be produced by means of this waste-free process.
Collapse
Affiliation(s)
- Nan Wang
- Department of Fine Chemicals, East China University of Science & Technology, Meilong Rd. 130, Shanghai, 200237, China. Fax: 86-21-64253881; Tel: 86-21-64252390
| | - Ronghua Wang
- Department of Fine Chemicals, East China University of Science & Technology, Meilong Rd. 130, Shanghai, 200237, China. Fax: 86-21-64253881; Tel: 86-21-64252390
| | - Xia Shi
- Department of Fine Chemicals, East China University of Science & Technology, Meilong Rd. 130, Shanghai, 200237, China. Fax: 86-21-64253881; Tel: 86-21-64252390
| | - Gang Zou
- Department of Fine Chemicals, East China University of Science & Technology, Meilong Rd. 130, Shanghai, 200237, China. Fax: 86-21-64253881; Tel: 86-21-64252390
| |
Collapse
|
28
|
Xia Z, Correa RG, Das JK, Farhana L, Castro DJ, Yu J, Oshima RG, Fontana JA, Reed JC, Dawson MI. Analogues of Orphan Nuclear Receptor Small Heterodimer Partner Ligand and Apoptosis Inducer (E)-4-[3-(1-Adamantyl)-4-hydroxyphenyl]-3-chlorocinnamic Acid. 2. Impact of 3-Chloro Group Replacement on Inhibition of Proliferation and Induction of Apoptosis of Leukemia and Cancer Cell Lines. J Med Chem 2011; 55:233-49. [DOI: 10.1021/jm2011436] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Affiliation(s)
- Zebin Xia
- Cancer Center, Sanford-Burnham Medical Research Institute, La Jolla, California 92037,
United States
| | - Ricardo G. Correa
- Cancer Center, Sanford-Burnham Medical Research Institute, La Jolla, California 92037,
United States
| | - Jayanta K. Das
- Department of Veterans Affairs Medical Center and Wayne State University School of Medicine, Detroit,
Michigan 48201,
United States
| | - Lulu Farhana
- Department of Veterans Affairs Medical Center and Wayne State University School of Medicine, Detroit,
Michigan 48201,
United States
| | - David J. Castro
- Cancer Center, Sanford-Burnham Medical Research Institute, La Jolla, California 92037,
United States
| | - Jinghua Yu
- Cancer Center, Sanford-Burnham Medical Research Institute, La Jolla, California 92037,
United States
| | - Robert G. Oshima
- Cancer Center, Sanford-Burnham Medical Research Institute, La Jolla, California 92037,
United States
| | - Joseph A. Fontana
- Department of Veterans Affairs Medical Center and Wayne State University School of Medicine, Detroit,
Michigan 48201,
United States
| | - John C. Reed
- Cancer Center, Sanford-Burnham Medical Research Institute, La Jolla, California 92037,
United States
| | - Marcia I. Dawson
- Cancer Center, Sanford-Burnham Medical Research Institute, La Jolla, California 92037,
United States
| |
Collapse
|
29
|
Lange TS, Horan TC, Kim KK, Singh AP, Vorsa N, Brard L, Moore RG, Singh RK. Cytotoxic Properties of Adamantyl Isothiocyanate and Potential In vivo Metabolite Adamantyl-N-Acetylcystein in Gynecological Cancer Cells. Chem Biol Drug Des 2011; 79:92-103. [DOI: 10.1111/j.1747-0285.2011.01251.x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
30
|
Demmer CS, Krogsgaard-Larsen N, Bunch L. Review on modern advances of chemical methods for the introduction of a phosphonic acid group. Chem Rev 2011; 111:7981-8006. [PMID: 22010799 DOI: 10.1021/cr2002646] [Citation(s) in RCA: 404] [Impact Index Per Article: 31.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Affiliation(s)
- Charles S Demmer
- Department of Medicinal Chemistry, Faculty of Pharmaceutical Sciences, University of Copenhagen, Universitetsparken 2, DK-2100 Copenhagen, Denmark
| | | | | |
Collapse
|
31
|
The many faces of the adamantyl group in drug design. Eur J Med Chem 2011; 46:1949-63. [DOI: 10.1016/j.ejmech.2011.01.047] [Citation(s) in RCA: 202] [Impact Index Per Article: 15.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2010] [Revised: 01/14/2011] [Accepted: 01/25/2011] [Indexed: 12/22/2022]
|
32
|
Miao J, Choi SE, Seok SM, Yang L, Zuercher WJ, Xu Y, Willson TM, Xu HE, Kemper JK. Ligand-dependent regulation of the activity of the orphan nuclear receptor, small heterodimer partner (SHP), in the repression of bile acid biosynthetic CYP7A1 and CYP8B1 genes. Mol Endocrinol 2011; 25:1159-69. [PMID: 21566081 DOI: 10.1210/me.2011-0033] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023] Open
Abstract
Small heterodimer partner (SHP) plays important roles in diverse biological processes by directly interacting with transcription factors and inhibiting their activities. SHP has been designated an orphan nuclear receptor, but whether its activity can be modulated by ligands has been a long-standing question. Recently, retinoid-related molecules, including 4-[3-(1-adamantyl)-4-hydroxyphenyl]-3-chlorocinnamic acid (3Cl-AHPC), were shown to bind to SHP and enhance apoptosis. We have examined whether 3Cl-AHPC acts as an agonist and increases SHP activity in the repression of bile acid biosynthetic CYP7A1 and CYP8B1 genes and delineated the underlying mechanisms. Contrary to this expectation, micromolar concentrations of 3Cl-AHPC increased CYP7A1 expression but indirectly via p38 kinase signaling. Nanomolar concentrations, however, repressed CYP7A1 expression and decreased bile acid levels in HepG2 cells, and little repression was observed when SHP was down-regulated by small hairpin RNA. Mechanistic studies revealed that 3Cl-AHPC bound to SHP, increased the interaction of SHP with liver receptor homologue (LRH)-1, a hepatic activator for CYP7A1 and CYP8B1 genes, and with repressive cofactors, Brahma, mammalian Sin3a, and histone deacetylase-1, and, subsequently, increased the occupancy of SHP and these cofactors at the promoters. Mutation of Leu-100, predicted to contact 3Cl-AHPC within the SHP ligand binding pocket by molecular modeling, severely impaired the increased interaction with LRH-1, and repression of LRH-1 activity mediated by 3Cl-AHPC. 3Cl-AHPC repressed SHP metabolic target genes in a gene-specific manner in human primary hepatocytes and HepG2 cells. These data suggest that SHP may act as a ligand-regulated receptor in metabolic pathways. Modulation of SHP activity by synthetic ligands may be a useful therapeutic strategy.
Collapse
Affiliation(s)
- Ji Miao
- Department of Molecular and Integrative Physiology, University of Illinois, Urbana-Champaign, Urbana, Illinois 61801, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Xia Z, Farhana L, Correa RG, Das JK, Castro DJ, Yu J, Oshima RG, Reed JC, Fontana JA, Dawson MI. Heteroatom-Substituted Analogues of Orphan Nuclear Receptor Small Heterodimer Partner Ligand and Apoptosis Inducer (E)-4-[3-(1-Adamantyl)-4-hydroxyphenyl]-3-chlorocinnamic Acid. J Med Chem 2011; 54:3793-816. [DOI: 10.1021/jm200051z] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Zebin Xia
- Cancer Center, Sanford-Burnham Medical Research Institute, La Jolla, California 92037, United States
| | - Lulu Farhana
- Department of Veterans Affairs Medical Center and Wayne State University School of Medicine, Detroit, Michigan 48201, United States
| | - Ricardo G. Correa
- Cancer Center, Sanford-Burnham Medical Research Institute, La Jolla, California 92037, United States
| | - Jayanta K. Das
- Department of Veterans Affairs Medical Center and Wayne State University School of Medicine, Detroit, Michigan 48201, United States
| | - David J. Castro
- Cancer Center, Sanford-Burnham Medical Research Institute, La Jolla, California 92037, United States
| | - Jinghua Yu
- Cancer Center, Sanford-Burnham Medical Research Institute, La Jolla, California 92037, United States
| | - Robert G. Oshima
- Cancer Center, Sanford-Burnham Medical Research Institute, La Jolla, California 92037, United States
| | - John C. Reed
- Cancer Center, Sanford-Burnham Medical Research Institute, La Jolla, California 92037, United States
| | - Joseph A. Fontana
- Department of Veterans Affairs Medical Center and Wayne State University School of Medicine, Detroit, Michigan 48201, United States
| | - Marcia I. Dawson
- Cancer Center, Sanford-Burnham Medical Research Institute, La Jolla, California 92037, United States
| |
Collapse
|
34
|
Nuclear receptor small heterodimer partner in apoptosis signaling and liver cancer. Cancers (Basel) 2011; 3:198-212. [PMID: 24212613 PMCID: PMC3756356 DOI: 10.3390/cancers3010198] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2010] [Revised: 12/30/2010] [Accepted: 01/04/2011] [Indexed: 01/01/2023] Open
Abstract
Small heterodimer partner (SHP, NR0B2) is a unique orphan nuclear receptor that contains the dimerization and a putative ligand-binding domain, but lacks the conserved DNA binding domain. SHP exerts its physiological function as an inhibitor of gene transcription through physical interaction with multiple nuclear receptors and transcriptional factors. SHP is a critical transcriptional regulator affecting diverse biological functions, including bile acid, cholesterol and lipid metabolism, glucose and energy homeostasis, and reproductive biology. Recently, we and others have demonstrated that SHP is an epigenetically regulated transcriptional repressor that suppresses the development of liver cancer. In this review, we summarize recent major findings regarding the role of SHP in cell proliferation, apoptosis, and DNA methylation, and discuss recent progress in understanding the function of SHP as a tumor suppressor in the development of liver cancer. Future study will be focused on identifying SHP associated novel pro-oncogenes and anti-oncogenes in liver cancer progression and applying the knowledge gained on SHP in liver cancer prevention, diagnosis and treatment.
Collapse
|
35
|
Zhang Y, Hagedorn CH, Wang L. Role of nuclear receptor SHP in metabolism and cancer. Biochim Biophys Acta Mol Basis Dis 2010; 1812:893-908. [PMID: 20970497 DOI: 10.1016/j.bbadis.2010.10.006] [Citation(s) in RCA: 185] [Impact Index Per Article: 13.2] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2010] [Revised: 10/12/2010] [Accepted: 10/14/2010] [Indexed: 02/07/2023]
Abstract
Small heterodimer partner (SHP, NR0B2) is a unique member of the nuclear receptor (NR) superfamily that contains the dimerization and ligand-binding domain found in other family members, but lacks the conserved DNA-binding domain. The ability of SHP to bind directly to multiple NRs is crucial for its physiological function as a transcriptional inhibitor of gene expression. A wide variety of interacting partners for SHP have been identified, indicating the potential for SHP to regulate an array of genes in different biological pathways. In this review, we summarize studies concerning the structure and target genes of SHP and discuss recent progress in understanding the function of SHP in bile acid, cholesterol, triglyceride, glucose, and drug metabolism. In addition, we review the regulatory role of SHP in microRNA (miRNA) regulation, liver fibrosis and cancer progression. The fact that SHP controls a complex set of genes in multiple metabolic pathways suggests the intriguing possibility of developing new therapeutics for metabolic diseases, including fatty liver, dyslipidemia and obesity, by regulating SHP with small molecules. To achieve this goal, more progress regarding SHP ligands and protein structure will be required. Besides its metabolic regulatory function, studies by us and other groups provide strong evidence that SHP plays a critical role in the development of cancer, particularly liver and breast cancer. An increased understanding of the fundamental mechanisms by which SHP regulates the development of cancers will be critical in applying knowledge of SHP in diagnostic, therapeutic or preventive strategies for specific cancers. This article is part of a Special Issue entitled: Translating nuclear receptors from health to disease.
Collapse
Affiliation(s)
- Yuxia Zhang
- Department of Medicine, Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT 84132, USA
| | | | | |
Collapse
|
36
|
Cellanetti M, Gunda V, Wang L, Macchiarulo A, Pellicciari R. Insights into the binding mode and mechanism of action of some atypical retinoids as ligands of the small heterodimer partner (SHP). J Comput Aided Mol Des 2010; 24:943-56. [PMID: 20882396 DOI: 10.1007/s10822-010-9386-9] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2010] [Accepted: 09/17/2010] [Indexed: 01/03/2023]
Abstract
The Small Heterodimer Partner (SHP) is an orphan nuclear receptor and an atypical member of the nuclear receptor superfamily Since its discovery, a growing body of evidences have pointed out a pivotal role for SHP in the transcriptional regulation of a variety of target genes involved in diverse metabolic pathways. While we have previously developed a homology model of the structure of SHP that was instrumental to identify a putative ligand binding pocket and suggest the possibility of the development of synthetic modulators, others reported that some atypical retinoids may represent the first synthetic ligands for this receptor. In this work, we report a combined computational approach aimed at shedding further lights on the binding mode and mechanism of action of some atypical retinoids as ligands of SHP. The results have been instrumental to design mutagenesis experiments whose preliminary data suggest the presence of a functional site in SHP as defined by residues Phe96, Arg138 and Arg238. While further experimental studies are ongoing, these findings constitute the basis for the design and identification of novel synthetic modulators of SHP functions.
Collapse
Affiliation(s)
- Marco Cellanetti
- Dipartimento di Chimica e Tecnologia del Farmaco, Università di Perugia, Italy
| | | | | | | | | |
Collapse
|
37
|
De P, Baltas M, Lamoral-Theys D, Bruyère C, Kiss R, Bedos-Belval F, Saffon N. Synthesis and anticancer activity evaluation of 2(4-alkoxyphenyl)cyclopropyl hydrazides and triazolo phthalazines. Bioorg Med Chem 2010; 18:2537-48. [DOI: 10.1016/j.bmc.2010.02.041] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2009] [Revised: 02/16/2010] [Accepted: 02/21/2010] [Indexed: 11/25/2022]
|
38
|
Dawson MI, Ye M, Cao X, Farhana L, Hu QY, Zhao Y, Xu LP, Kiselyuk A, Correa RG, Yang L, Hou T, Reed JC, Itkin-Ansari P, Levine F, Sanner MF, Fontana JA, Zhang XK. Derivation of a retinoid X receptor scaffold from peroxisome proliferator-activated receptor gamma ligand 1-Di(1H-indol-3-yl)methyl-4-trifluoromethylbenzene. ChemMedChem 2009; 4:1106-19. [PMID: 19378296 DOI: 10.1002/cmdc.200800447] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
PPARgamma agonist DIM-Ph-4-CF(3), a template for RXRalpha agonist (E)-3-[5-di(1-methyl-1H-indol-3-yl)methyl-2-thienyl] acrylic acid: DIM-Ph-CF(3) is reported to inhibit cancer growth independent of PPARgamma and to interact with NR4A1. As both receptors dimerize with RXR, and natural PPARgamma ligands activate RXR, DIM-Ph-4-CF(3) was investigated as an RXR ligand. It displaces 9-cis-retinoic acid from RXRalpha but does not activate RXRalpha. Structure-based direct design led to an RXRalpha agonist.1-Di(1H-indol-3-yl)methyl-4-trifluoromethylbenzene (DIM-Ph-4-CF(3)) is reported to inhibit cancer cell growth and to act as a transcriptional agonist of peroxisome proliferator-activated receptor gamma (PPARgamma) and nuclear receptor 4A subfamily member 1 (NR4A1). In addition, DIM-Ph-4-CF(3) exerts anticancer effects independent of these receptors because PPARgamma antagonists do not block its inhibition of cell growth, and the small pocket in the NR4A1 crystal structure suggests no ligand can bind. Because PPARgamma and NR4A1 heterodimerize with retinoid X receptor (RXR), and several PPARgamma ligands transcriptionally activate RXR, DIM-Ph-4-CF(3) was investigated as an RXR ligand. DIM-Ph-4-CF(3) displaces 9-cis-retinoic acid from RXRalpha but does not transactivate RXRalpha. Structure-based design using DIM-Ph-4-CF(3) as a template led to the RXRalpha transcriptional agonist (E)-3-[5-di(1-methyl-1H-indol-3-yl)methyl-2-thienyl]acrylic acid. Its docked pose in the RXRalpha ligand binding domain suggests that binding is stabilized by interactions of its carboxylate group with arginine 316, its indoles with cysteines 269 and 432, and its 1-methyl groups with hydrophobic residues lining the binding pocket. As is expected of a selective activator of RXRalpha, but not of RARs and PPARgamma, this RXRalpha agonist, unlike DIM-Ph-4-CF(3), does not appreciably decrease cancer cell growth or induce apoptosis at pharmacologically relevant concentrations.
Collapse
Affiliation(s)
- Marcia I Dawson
- Cancer Center, Burnham Institute for Medical Research, 10901 North Torrey Pines Rd., La Jolla, CA 92037, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Farhana L, Dawson MI, Dannenberg JH, Xu L, Fontana JA. SHP and Sin3A expression are essential for adamantyl-substituted retinoid-related molecule-mediated nuclear factor-kappaB activation, c-Fos/c-Jun expression, and cellular apoptosis. Mol Cancer Ther 2009; 8:1625-35. [PMID: 19509248 DOI: 10.1158/1535-7163.mct-08-0964] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
We previously found that the adamantyl-substituted retinoid-related molecules bind to the small heterodimer partner (SHP) as well as the Sin3A complex. In this report, we delineated the role of SHP and the Sin3A complex in 4-[3'-(1-adamantyl)-4'-hydroxyphenyl]-3-chlorocinnamic acid (3-Cl-AHPC)-mediated inhibition of cell growth and apoptosis. We examined the effect of loss of SHP and Sin3A expression in a number of cell types on 3-Cl-AHPC-mediated growth inhibition and apoptosis induction, 3-Cl-AHPC-mediated nuclear factor-kappaB (NF-kappaB) activation, and 3-Cl-AHPC-mediated increase in c-Fos and c-Jun expression. We found that loss of SHP or Sin3A expression, while blocking 3-Cl-AHPC-mediated apoptosis, had little effect on 3-Cl-AHPC inhibition of cellular proliferation. We have previously shown that 3-Cl-AHPC-mediated NF-kappaB activation is necessary for apoptosis induction. We have now shown that 3-Cl-AHPC-enhanced c-Fos and c-Jun expression is also essential for maximal 3-Cl-AHPC-mediated apoptosis. 3-Cl-AHPC induction of c-Fos and c-Jun expression as well as NF-kappaB activation was dependent on SHP protein levels. In turn, SHP levels are regulated by Sin3A because ablation of Sin3A resulted in a decrease in SHP expression. Thus, SHP and Sin3A play an important role in adamantyl-substituted retinoid-related induction of cellular apoptosis.
Collapse
Affiliation(s)
- Lulu Farhana
- John D. Dingell VA Medical Center, Oncology 11M-HO, 4646 John R. Street, Detroit, MI 48201, USA
| | | | | | | | | |
Collapse
|
40
|
Ye M, Dawson MI. Studies of cannabinoid-1 receptor antagonists for the treatment of obesity: Hologram QSAR model for biarylpyrazolyl oxadiazole ligands. Bioorg Med Chem Lett 2009; 19:3310-5. [DOI: 10.1016/j.bmcl.2009.04.072] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2008] [Revised: 04/15/2009] [Accepted: 04/17/2009] [Indexed: 10/20/2022]
|
41
|
Spallarossa A, Cesarini S, Schenone S, Ranise A. Parallel Synthesis ofO‐Phenoxyethyl andO‐AdamantylN‐acyl Thiocarbamates Endowed with Antiproliferative Activity. Arch Pharm (Weinheim) 2009; 342:344-52. [DOI: 10.1002/ardp.200800212] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
42
|
Pérez-Rodríguez S, Ortiz MA, Pereira R, Rodríguez-Barrios F, de Lera AR, Piedrafita FJ. Highly twisted adamantyl arotinoids: synthesis, antiproliferative effects and RXR transactivation profiles. Eur J Med Chem 2009; 44:2434-46. [PMID: 19216008 DOI: 10.1016/j.ejmech.2009.01.011] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2008] [Revised: 12/20/2008] [Accepted: 01/09/2009] [Indexed: 12/23/2022]
Abstract
Retinoid-related molecules with an adamantyl group (adamantyl arotinoids) have been described with selective activities towards the retinoid receptors as agonists for NR1B2 and NR1B3 (RARbeta,gamma) (CD437, MX3350-1) or RAR antagonists (MX781) that induce growth arrest and apoptosis in cancer cells. Since these molecules induce apoptosis independently of RAR transactivation, we set up to synthesize novel analogs with impaired RAR binding. Here we describe adamantyl arotinoids with 2,2'-disubstituted biaryl rings prepared using the Suzuki coupling of the corresponding fragments. Those with cinnamic and naphthoic acid end groups showed significant antiproliferative activity in several cancer cell lines, and this effect correlated with the induction of apoptosis as measured by caspase activity. Strikingly, some of these compounds, whereas devoid of RAR binding capacity, were able to activate RXR.
Collapse
|
43
|
Maran RRM, Thomas A, Roth M, Sheng Z, Esterly N, Pinson D, Gao X, Zhang Y, Ganapathy V, Gonzalez FJ, Guo GL. Farnesoid X receptor deficiency in mice leads to increased intestinal epithelial cell proliferation and tumor development. J Pharmacol Exp Ther 2008; 328:469-77. [PMID: 18981289 DOI: 10.1124/jpet.108.145409] [Citation(s) in RCA: 177] [Impact Index Per Article: 11.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
Increased dietary fat consumption is associated with colon cancer development. The exact mechanism by which fat induces colon cancer is not clear, however, increased bile acid excretion in response to high-fat diet may promote colon carcinogenesis. The farnesoid X receptor (FXR) is a member of the nuclear receptor superfamily, and bile acids are endogenous ligands of FXR. FXR is highly expressed in the intestine and liver where FXR is essential for maintaining bile acid homeostasis. The role of FXR in intestine cancer development is not known. The current study evaluated the effects of FXR deficiency in mice on intestinal cell proliferation and cancer development. The results showed that FXR deficiency resulted in increased colon cell proliferation, which was accompanied by an up-regulation in the expression of genes involved in cell cycle progression and inflammation, including cyclin D1 and interleukin-6. Most importantly, FXR deficiency led to an increase in the size of small intestine adenocarcinomas in adenomatous polyposis coli mutant mice. Furthermore, after treatment with a colon carcinogen, azoxymethane, FXR deficiency increased the adenocarcinoma multiplicity and size in colon and rectum of C57BL/6 mice. Loss of FXR function also increased the intestinal lymphoid nodule numbers in the intestine. Taken together, the current study is the first to show that FXR deficiency promotes cell proliferation, inflammation, and tumorigenesis in the intestine, suggesting that activation of FXR by nonbile acid ligands may protect against intestinal carcinogenesis.
Collapse
Affiliation(s)
- Rengasamy R M Maran
- Department of Pharmacology, Toxicology and, Therapeutics, University of Kansas Medical Center, Kansas City, KS 66160, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
44
|
Dawson MI, Xia Z, Jiang T, Ye M, Fontana JA, Farhana L, Patel B, Xue LP, Bhuiyan M, Pellicciari R, Macchiarulo A, Nuti R, Zhang XK, Han YH, Tautz L, Hobbs PD, Jong L, Waleh N, Chao WR, Feng GS, Pang Y, Su Y. Adamantyl-substituted retinoid-derived molecules that interact with the orphan nuclear receptor small heterodimer partner: effects of replacing the 1-adamantyl or hydroxyl group on inhibition of cancer cell growth, induction of cancer cell apoptosis, and inhibition of SRC homology 2 domain-containing protein tyrosine phosphatase-2 activity. J Med Chem 2008; 51:5650-62. [PMID: 18759424 DOI: 10.1021/jm800456k] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
(E)-4-[3-(1-Adamantyl)-4'-hydroxyphenyl]-3-chlorocinnamic acid (3-Cl-AHPC) induces the cell-cycle arrest and apoptosis of leukemia and cancer cells. Studies demonstrated that 3-Cl-AHPC bound to the atypical orphan nuclear receptor small heterodimer partner (SHP). Although missing a DNA-binding domain, SHP heterodimerizes with the ligand-binding domains of other nuclear receptors to repress their abilities to induce or inhibit gene expression. 3-Cl-AHPC analogues having the 1-adamantyl and phenolic hydroxyl pharmacophoric elements replaced with isosteric groups were designed, synthesized, and evaluated for their inhibition of proliferation and induction of human cancer cell apoptosis. Structure-anticancer activity relationship studies indicated the importance of both groups to apoptotic activity. Docking of 3-Cl-AHPC and its analogues to an SHP computational model that was based on the crystal structure of ultraspiracle complexed with 1-stearoyl-2-palmitoylglycero-3-phosphoethanolamine suggested why these 3-Cl-AHPC groups could influence SHP activity. Inhibitory activity against Src homology 2 domain-containing protein tyrosine phosphatase 2 (Shp-2) was also assessed. The most active Shp-2 inhibitor was found to be the 3'-(3,3-dimethylbutynyl) analogue of 3-Cl-AHPC.
Collapse
Affiliation(s)
- Marcia I Dawson
- Cancer Center and Inflammatory and Infectious Disease Center, Burnham Institute for Medical Research, La Jolla, California 92037, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Lorenzo P, Alvarez R, Ortiz MA, Alvarez S, Piedrafita FJ, de Lera ÁR. Inhibition of IκB Kinase-β and Anticancer Activities of Novel Chalcone Adamantyl Arotinoids. J Med Chem 2008; 51:5431-40. [DOI: 10.1021/jm800285f] [Citation(s) in RCA: 62] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Paula Lorenzo
- Departamento de Química Orgánica, Universidade de Vigo, Lagoas-Marcosende, 36310 Vigo, Spain, and Sidney Kimmel Cancer Center, 10905 Road to the Cure, San Diego, California 92121
| | - Rosana Alvarez
- Departamento de Química Orgánica, Universidade de Vigo, Lagoas-Marcosende, 36310 Vigo, Spain, and Sidney Kimmel Cancer Center, 10905 Road to the Cure, San Diego, California 92121
| | - Maria A. Ortiz
- Departamento de Química Orgánica, Universidade de Vigo, Lagoas-Marcosende, 36310 Vigo, Spain, and Sidney Kimmel Cancer Center, 10905 Road to the Cure, San Diego, California 92121
| | - Susana Alvarez
- Departamento de Química Orgánica, Universidade de Vigo, Lagoas-Marcosende, 36310 Vigo, Spain, and Sidney Kimmel Cancer Center, 10905 Road to the Cure, San Diego, California 92121
| | - F. Javier Piedrafita
- Departamento de Química Orgánica, Universidade de Vigo, Lagoas-Marcosende, 36310 Vigo, Spain, and Sidney Kimmel Cancer Center, 10905 Road to the Cure, San Diego, California 92121
| | - Ángel R. de Lera
- Departamento de Química Orgánica, Universidade de Vigo, Lagoas-Marcosende, 36310 Vigo, Spain, and Sidney Kimmel Cancer Center, 10905 Road to the Cure, San Diego, California 92121
| |
Collapse
|
46
|
Simoni D, Rondanin R, Baruchello R, Rizzi M, Grisolia G, Eleopra M, Grimaudo S, Cristina AD, Pipitone MR, Bongiorno MR, Aricò M, Invidiata FP, Tolomeo M. Novel Terphenyls and 3,5-Diaryl Isoxazole Derivatives Endowed with Growth Supporting and Antiapoptotic Properties. J Med Chem 2008; 51:4796-803. [DOI: 10.1021/jm800388m] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Daniele Simoni
- Dipartimento di Scienze Farmaceutiche, Università di Ferrara, via Fossato di Mortara 17/19, I-44100 Ferrara, Italy, Dipartimento Biomedico di Medicina Interna e Specialistica, Università di Palermo, Italy, Cattedra di Dermatologia. Università di Palermo, Dipartimento Farmacochimico Tossicologico e Biologico, Università di Palermo, Centro Interdipartimentale di Ricerca in Oncologia Clinica (C.I.R.O.C.) e Servizio AIDS, Palermo, Italy
| | - Riccardo Rondanin
- Dipartimento di Scienze Farmaceutiche, Università di Ferrara, via Fossato di Mortara 17/19, I-44100 Ferrara, Italy, Dipartimento Biomedico di Medicina Interna e Specialistica, Università di Palermo, Italy, Cattedra di Dermatologia. Università di Palermo, Dipartimento Farmacochimico Tossicologico e Biologico, Università di Palermo, Centro Interdipartimentale di Ricerca in Oncologia Clinica (C.I.R.O.C.) e Servizio AIDS, Palermo, Italy
| | - Riccardo Baruchello
- Dipartimento di Scienze Farmaceutiche, Università di Ferrara, via Fossato di Mortara 17/19, I-44100 Ferrara, Italy, Dipartimento Biomedico di Medicina Interna e Specialistica, Università di Palermo, Italy, Cattedra di Dermatologia. Università di Palermo, Dipartimento Farmacochimico Tossicologico e Biologico, Università di Palermo, Centro Interdipartimentale di Ricerca in Oncologia Clinica (C.I.R.O.C.) e Servizio AIDS, Palermo, Italy
| | - Michele Rizzi
- Dipartimento di Scienze Farmaceutiche, Università di Ferrara, via Fossato di Mortara 17/19, I-44100 Ferrara, Italy, Dipartimento Biomedico di Medicina Interna e Specialistica, Università di Palermo, Italy, Cattedra di Dermatologia. Università di Palermo, Dipartimento Farmacochimico Tossicologico e Biologico, Università di Palermo, Centro Interdipartimentale di Ricerca in Oncologia Clinica (C.I.R.O.C.) e Servizio AIDS, Palermo, Italy
| | - Giuseppina Grisolia
- Dipartimento di Scienze Farmaceutiche, Università di Ferrara, via Fossato di Mortara 17/19, I-44100 Ferrara, Italy, Dipartimento Biomedico di Medicina Interna e Specialistica, Università di Palermo, Italy, Cattedra di Dermatologia. Università di Palermo, Dipartimento Farmacochimico Tossicologico e Biologico, Università di Palermo, Centro Interdipartimentale di Ricerca in Oncologia Clinica (C.I.R.O.C.) e Servizio AIDS, Palermo, Italy
| | - Marco Eleopra
- Dipartimento di Scienze Farmaceutiche, Università di Ferrara, via Fossato di Mortara 17/19, I-44100 Ferrara, Italy, Dipartimento Biomedico di Medicina Interna e Specialistica, Università di Palermo, Italy, Cattedra di Dermatologia. Università di Palermo, Dipartimento Farmacochimico Tossicologico e Biologico, Università di Palermo, Centro Interdipartimentale di Ricerca in Oncologia Clinica (C.I.R.O.C.) e Servizio AIDS, Palermo, Italy
| | - Stefania Grimaudo
- Dipartimento di Scienze Farmaceutiche, Università di Ferrara, via Fossato di Mortara 17/19, I-44100 Ferrara, Italy, Dipartimento Biomedico di Medicina Interna e Specialistica, Università di Palermo, Italy, Cattedra di Dermatologia. Università di Palermo, Dipartimento Farmacochimico Tossicologico e Biologico, Università di Palermo, Centro Interdipartimentale di Ricerca in Oncologia Clinica (C.I.R.O.C.) e Servizio AIDS, Palermo, Italy
| | - Antonietta Di Cristina
- Dipartimento di Scienze Farmaceutiche, Università di Ferrara, via Fossato di Mortara 17/19, I-44100 Ferrara, Italy, Dipartimento Biomedico di Medicina Interna e Specialistica, Università di Palermo, Italy, Cattedra di Dermatologia. Università di Palermo, Dipartimento Farmacochimico Tossicologico e Biologico, Università di Palermo, Centro Interdipartimentale di Ricerca in Oncologia Clinica (C.I.R.O.C.) e Servizio AIDS, Palermo, Italy
| | - Maria Rosaria Pipitone
- Dipartimento di Scienze Farmaceutiche, Università di Ferrara, via Fossato di Mortara 17/19, I-44100 Ferrara, Italy, Dipartimento Biomedico di Medicina Interna e Specialistica, Università di Palermo, Italy, Cattedra di Dermatologia. Università di Palermo, Dipartimento Farmacochimico Tossicologico e Biologico, Università di Palermo, Centro Interdipartimentale di Ricerca in Oncologia Clinica (C.I.R.O.C.) e Servizio AIDS, Palermo, Italy
| | - Maria Rita Bongiorno
- Dipartimento di Scienze Farmaceutiche, Università di Ferrara, via Fossato di Mortara 17/19, I-44100 Ferrara, Italy, Dipartimento Biomedico di Medicina Interna e Specialistica, Università di Palermo, Italy, Cattedra di Dermatologia. Università di Palermo, Dipartimento Farmacochimico Tossicologico e Biologico, Università di Palermo, Centro Interdipartimentale di Ricerca in Oncologia Clinica (C.I.R.O.C.) e Servizio AIDS, Palermo, Italy
| | - Mario Aricò
- Dipartimento di Scienze Farmaceutiche, Università di Ferrara, via Fossato di Mortara 17/19, I-44100 Ferrara, Italy, Dipartimento Biomedico di Medicina Interna e Specialistica, Università di Palermo, Italy, Cattedra di Dermatologia. Università di Palermo, Dipartimento Farmacochimico Tossicologico e Biologico, Università di Palermo, Centro Interdipartimentale di Ricerca in Oncologia Clinica (C.I.R.O.C.) e Servizio AIDS, Palermo, Italy
| | - Francesco Paolo Invidiata
- Dipartimento di Scienze Farmaceutiche, Università di Ferrara, via Fossato di Mortara 17/19, I-44100 Ferrara, Italy, Dipartimento Biomedico di Medicina Interna e Specialistica, Università di Palermo, Italy, Cattedra di Dermatologia. Università di Palermo, Dipartimento Farmacochimico Tossicologico e Biologico, Università di Palermo, Centro Interdipartimentale di Ricerca in Oncologia Clinica (C.I.R.O.C.) e Servizio AIDS, Palermo, Italy
| | - Manlio Tolomeo
- Dipartimento di Scienze Farmaceutiche, Università di Ferrara, via Fossato di Mortara 17/19, I-44100 Ferrara, Italy, Dipartimento Biomedico di Medicina Interna e Specialistica, Università di Palermo, Italy, Cattedra di Dermatologia. Università di Palermo, Dipartimento Farmacochimico Tossicologico e Biologico, Università di Palermo, Centro Interdipartimentale di Ricerca in Oncologia Clinica (C.I.R.O.C.) e Servizio AIDS, Palermo, Italy
| |
Collapse
|
47
|
Chanda D, Park JH, Choi HS. Molecular basis of endocrine regulation by orphan nuclear receptor Small Heterodimer Partner. Endocr J 2008; 55:253-68. [PMID: 17984569 DOI: 10.1507/endocrj.k07e-103] [Citation(s) in RCA: 91] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
Nuclear receptors (NRs) are a unique superfamily of transcription factors (TFs) which are involved in and play a crucial role in almost all aspects of mammalian physiology. Small Heterodimer Partner (SHP; NR0B2), an exceptional member of this superfamily of NRs, have been identified as a key regulatory factor of the transcription of a variety of genes involved in diverse metabolic pathways, and are thereby an important factor in a variety of physiological functions. Since its discovery a decade ago, considerable progress has been made in the elucidation of the underlying mechanism by which SHP regulates various metabolic processes, and the results of previous studies support its importance in the maintenance of metabolic homeostasis. In this review, we have evaluated the current state of understanding of the molecular mechanisms and the resultant physiological interpretations governed by SHP.
Collapse
Affiliation(s)
- Dipanjan Chanda
- Hormone Research Center, School of Biological Sciences and Technology, Chonnam National University, Gwangju, Republic of Korea
| | | | | |
Collapse
|